Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: Drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system?

Clinical and Experimental Immunology

Volumn 167, Issue 1, 2012, Pages 1-6

  Meier, U C ^a   Giovannoni, G ^a   Tzartos, J S ^b   Khan, G ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b HELLENIC PASTEUR INSTITUTE   (Greece)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

B cells; Epstein Barr virus; Multiple sclerosis

Indexed keywords

OCRELIZUMAB; OFATUMUMAB; OLIGOCLONAL BAND; RITUXIMAB;

B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE ACTIVITY; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; IMMUNOREGULATION; INFECTIOUS MONONUCLEOSIS; INFLAMMATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS ENTRY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTE SUBSETS; CELL MOVEMENT; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS, PHASE II AS TOPIC; CLONE CELLS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTE DEPLETION; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS;

EID: 82655171685     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04446.x     Document Type: Review

References (61)

1. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010; 9:727-39.
2. Matthews W. Symptoms and signs of multiple sclerosis. In: Livingstone C, ed. McAlpine's multiple sclerosis, 3rd edn. London: Churchill Livingstone/Harcourt Brace & Co, 1998; 149-50.
3. Baker D, Gerritsen W, Rundle J, Amor S. Critical appraisal of animal models of multiple sclerosis. Mult Scler 2011; 17:149-50.
4. Hauser SL, Bhan AK, Gilles F, Kemp M, Kerr C, Weiner HL. Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol 1986; 19:578-87.
5. Nyland H, Mork S, Matre R. In-situ characterization of mononuclear cell infiltrates in lesions of multiple sclerosis. Neuropathol Appl Neurobiol 1982; 8:403-11.
6. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. Science 1983; 219:308-10.
7. Woodroofe MN, Bellamy AS, Feldmann M, Davison AN, Cuzner ML. Immunocytochemical characterisation of the immune reaction in the central nervous system in multiple sclerosis. Possible role for microglia in lesion growth. J Neurol Sci 1986; 74:135-52.
8. Booss J, Esiri M, Tourtellotte W, Mason D. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci 1983; 62:219-32.
9. Esiri MM. Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet 1977; 2:478.
10. Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978; 38:409-21.
11. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997; 120:1461-83.
12. Tzartos JS, Friese MA, Craner MJ etal. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008; 172:146-55.
13. Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14:164-74.
14. Magliozzi R, Howell O, Vora A etal. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130:1089-104.
15. Magliozzi R, Howell OW, Reeves C etal. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68:477-93.
16. Obermeier B, Mentele R, Malotka J etal. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 2008; 14:688-93.
17. Owens GP, Bennett JL, Lassmann H etal. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 2009; 65:639-49.
18. Lowenthal A, Van Sande M, Karcher D. Serum gamma globulins in 84 typical cases of subacute sclerosing panencephalitis. Neurology 1971; 21:277-80.
19. Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998; 102:1045-50.
20. Colombo M, Dono M, Gazzola P etal. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 2000; 164:2782-9.
21. Burgoon MP, Cohrs RJ, Bennett JL etal. Varicella zoster virus is not a disease-relevant antigen in multiple sclerosis. Ann Neurol 2009; 65:474-9.
22. Bennett J. The targets of cerebrospinal fluid oligoclonal bands in multiple sclerosis. Keystone Meeting: 'Genetics, Immunology and Repair in Multiple Sclerosis', Taos, New Mexico, 2011:49.
23. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999; 163:5133-44.
24. Lovato L, Willis S, Rodig S etal. B cells and antibodies in the MS CNS. Keystone Meeting: 'Genetics, Immunology and Repair in Multiple Sclerosis', Taos, New Mexico 2011:48.
25. Obermeier B, Lovato L, Mentele R etal. Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J Neuroimmunol 2011; 233:245-8.
26. Serafini B, Rosicarelli B, Franciotta D etal. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204:2899-912.
27. Epstein M, Achong B, Barr Y. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet Neurol 1964; 1:702-3.
28. Straus S, Cohen J, Tosato G, Meier J. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 1993; 118:45-58.
29. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 2004; 350:1328-37.
30. Hutt-Fletcher LM. Epstein-Barr virus entry. J Virol 2007; 81:7825-32.
31. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4:757-68.
32. Hislop AD, Ressing ME, van Leeuwen D etal. A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med 2007; 204:1863-73.
33. Callan MF, Steven N, Krausa P etal. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med 1996; 2:906-11.
34. Khan G, Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson DA. Is EBV persistence in vivo a model for B cell homeostasis? Immunity 1996; 5:173-9.
35. Rickinson A. Epstein-Barr virus. Virus Res 2002; 82:109-13.
36. Wakiguchi H. Overview of Epstein-Barr virus-associated diseases in Japan. Crit Rev Oncol Hematol 2002; 44:193-202.
37. Niller HH, Wolf H, Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 2008; 41:298-328.
38. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006; 59:499-503.
39. Handel AE, Williamson AJ, Disanto G, Handunnetthi L, Giovannoni G, Ramagopalan SV. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE 2010; 5:pii:e12496.
40. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007; 61:288-99.
41. Farrell RA, Antony D, Wall GR etal. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 2009; 73:32-8.
42. Lang HL, Jacobsen H, Ikemizu S etal. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002; 3:940-3.
43. Willis SN, Stadelmann C, Rodig SJ etal. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 2009; 132:3318-28.
44. Peferoen LA, Lamers F, Lodder LN etal. Epstein-Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 2010; 133 (Pt 5):e137.
45. Sargsyan SA, Shearer AJ, Ritchie AM etal. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 2010; 74:1127-35.
46. Khan G, Coates PJ, Kangro HO, Slavin G. Epstein Barr virus (EBV) encoded small RNAs: targets for detection by in situ hybridisation with oligonucleotide probes. J Clin Pathol 1992; 45:616-20.
47. Tzartos J, Khan G, Vossenkamper A etal. Activation of innate immune responses is a hallmark of the active lesion in multiple sclerosis. Keystone Meeting: 'Genetics, Immunology and Repair in Multiple Sclerosis', Taos, New Mexico, 2011:76.
48. Iwakiri D, Zhou L, Samanta M etal. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009; 206:2091-9.
49. Hauser SL, Waubant E, Arnold DL etal. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676-88.
50. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15:450-4.
51. Bemark M, Holmqvist J, Abrahamsson J, Mellgren K. Translational Mini-Review Series: B cell subsets in disease. Reconstitution after haematopoietic stem cell transplantation - revelation of B cell developmental pathways and lineage phenotypes. Clin Exp Immunol 2012; 167:15-25.
52. Petereit HF, Moeller-Hartmann W, Reske D, Rubbert A. Rituximab in a patient with multiple sclerosis - effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2008; 117:399-403.
53. Hawker K, O'Connor P, Freedman MS etal. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66:460-71.
54. Buttmann M, Wiendl H. [Therapeutic monoclonal antibodies in clinical neurology]. Nervenarzt 2010; 81:753-64 quiz 65-6.
55. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK. Visualization of specific B and T lymphocyte interactions in the lymph node. Science 1998; 281:96-9.
56. Bouaziz JD, Yanaba K, Venturi GM etal. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA 2007; 104:20878-83.
57. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H etal. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143-52.
58. Bar-Or A, Calabresi PA, Arnold D etal. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63:395-400.
59. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev 2008; 223:284-99.
60. Mann M, Maresz K, Shriver L, Tan Y, Dittel B. B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol 2007; 178:3447-56.
61. Weber MS, Prod'homme T, Patarroyo JC etal. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 2010; 68:369-83.